Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Unity Biotechnology reports granting of employment inducement awards » 08:15
07/28/21
07/28
08:15
07/28/21
08:15
UBX

Unity Biotechnology

$3.82 /

-0.005 (-0.13%)

UNITY Biotechnology…

UNITY Biotechnology announced that from July 13, 2021, through July 27, 2021, the Compensation Committee of the Board of Directors granted 3 new employees stock-based awards covering an aggregate of 41,900 shares of UNITY common stock, including options to purchase an aggregate of 41,900 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

ShowHide Related Items >><<
UBX Unity Biotechnology
$3.82 /

-0.005 (-0.13%)

UBX Unity Biotechnology
$3.82 /

-0.005 (-0.13%)

06/28/21 Citi
Unity Biotechnology double upgraded to Buy at Citi after 50% pullback
06/28/21 Citi
Unity Biotechnology upgraded to Buy from Sell at Citi
06/07/21 H.C. Wainwright
Unity Biotechnology initiated with a Buy at H.C. Wainwright
03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
UBX Unity Biotechnology
$3.82 /

-0.005 (-0.13%)

Tuesday
Conference/Events
Unity Biotechnology to host conference call » 10:55
07/27/21
07/27
10:55
07/27/21
10:55
UBX

Unity Biotechnology

$3.65 /

-0.175 (-4.58%)

Management, along with…

Management, along with Dr.Bhisitkul, Professor Ophthalmology of the Retina Fellowship at University of California, discuss clinical data from the Phase 1 study in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) patients treated with a single injection of UBX1325 on a conference call to be held on July 27 at 11 am. Webcast Link

ShowHide Related Items >><<
UBX Unity Biotechnology
$3.65 /

-0.175 (-4.58%)

UBX Unity Biotechnology
$3.65 /

-0.175 (-4.58%)

06/28/21 Citi
Unity Biotechnology double upgraded to Buy at Citi after 50% pullback
06/28/21 Citi
Unity Biotechnology upgraded to Buy from Sell at Citi
06/07/21 H.C. Wainwright
Unity Biotechnology initiated with a Buy at H.C. Wainwright
03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
UBX Unity Biotechnology
$3.65 /

-0.175 (-4.58%)

Conference/Events
Unity Biotechnology to host conference call » 04:55
07/27/21
07/27
04:55
07/27/21
04:55
UBX

Unity Biotechnology

$3.83 /

-0.045 (-1.16%)

Management, along with…

Management, along with Dr.Bhisitkul, Professor Ophthalmology of the Retina Fellowship at University of California, discuss clinical data from the Phase 1 study in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) patients treated with a single injection of UBX1325 on a conference call to be held on July 27 at 11 am. Webcast Link

ShowHide Related Items >><<
UBX Unity Biotechnology
$3.83 /

-0.045 (-1.16%)

UBX Unity Biotechnology
$3.83 /

-0.045 (-1.16%)

06/28/21 Citi
Unity Biotechnology double upgraded to Buy at Citi after 50% pullback
06/28/21 Citi
Unity Biotechnology upgraded to Buy from Sell at Citi
06/07/21 H.C. Wainwright
Unity Biotechnology initiated with a Buy at H.C. Wainwright
03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
UBX Unity Biotechnology
$3.83 /

-0.045 (-1.16%)

Over a week ago
Conference/Events
Unity Biotechnology to host conference call » 20:03
07/25/21
07/25
20:03
07/25/21
20:03
UBX

Unity Biotechnology

$3.89 /

+0.04 (+1.04%)

Management, along with…

Management, along with Dr.Bhisitkul, Professor Ophthalmology of the Retina Fellowship at University of California, discuss clinical data from the Phase 1 study in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) patients treated with a single injection of UBX1325 on a conference call to be held on July 27 at 11 am. Webcast Link

ShowHide Related Items >><<
UBX Unity Biotechnology
$3.89 /

+0.04 (+1.04%)

UBX Unity Biotechnology
$3.89 /

+0.04 (+1.04%)

06/28/21 Citi
Unity Biotechnology double upgraded to Buy at Citi after 50% pullback
06/28/21 Citi
Unity Biotechnology upgraded to Buy from Sell at Citi
06/07/21 H.C. Wainwright
Unity Biotechnology initiated with a Buy at H.C. Wainwright
03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
UBX Unity Biotechnology
$3.89 /

+0.04 (+1.04%)

Hot Stocks
Unity Biotechnology to host investor call on Phase 1 trial of UBX1325 » 08:07
07/23/21
07/23
08:07
07/23/21
08:07
UBX

Unity Biotechnology

$3.85 /

-0.15 (-3.75%)

UNITY Biotechnology…

UNITY Biotechnology announced that it will host a webcast for investors and analysts on July 27, 2021 at 8:00 a.m. Pacific Time to discuss clinical data from the Phase 1 study in diabetic macular edema and wet age-related macular degeneration patients treated with a single injection of UBX1325. At this webcast, Robert Bhisitkul, M.D., Ph.D., professor of ophthalmology and director of the Retina Fellowship at University of California, San Francisco, and members of UNITY senior management will present on recent safety and initial efficacy signals from UBX1325, including rapid improvements in best-corrected visual acuity, central subfield thickness and sub- and intra-retinal fluid (SRF, IRF) - all key clinical measures of disease progression, observed in a majority of trial subjects. Based on previous data announced, UNITY is currently enrolling additional patients with advanced wet AMD in the Phase 1 study to gather additional data to support a potential Phase 2a study in wet AMD. A parallel Phase 2a study in DME is currently enrolling.

ShowHide Related Items >><<
UBX Unity Biotechnology
$3.85 /

-0.15 (-3.75%)

UBX Unity Biotechnology
$3.85 /

-0.15 (-3.75%)

06/28/21 Citi
Unity Biotechnology double upgraded to Buy at Citi after 50% pullback
06/28/21 Citi
Unity Biotechnology upgraded to Buy from Sell at Citi
06/07/21 H.C. Wainwright
Unity Biotechnology initiated with a Buy at H.C. Wainwright
03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
UBX Unity Biotechnology
$3.85 /

-0.15 (-3.75%)

Hot Stocks
Unity Biotechnology announces data from Phase 1 study of UBX1325 » 07:06
07/06/21
07/06
07:06
07/06/21
07:06
UBX

Unity Biotechnology

$4.46 /

-0.04 (-0.89%)

UNITY Biotechnology…

UNITY Biotechnology announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from DME or wet AMD for whom anti-VEGF therapy was no longer considered beneficial. UBX1325, a small molecule inhibitor of Bcl-xL and the first senolytic therapeutic evaluated in an ophthalmological clinical study, was well-tolerated with no treatment-related adverse events or dose-limiting toxicities. Additionally, the majority of DME and wet AMD patients treated with a single injection of UBX1325 demonstrated rapid improvements in best-corrected visual acuity central subfield thickness and sub- and intra-retinal fluid all key clinical measures of disease progression. The first patient has been dosed in a Phase 2a clinical study to assess the safety and efficacy of UBX1325 in a broader population of patients with DME, and data is expected in the first half of 2022.

ShowHide Related Items >><<
UBX Unity Biotechnology
$4.46 /

-0.04 (-0.89%)

UBX Unity Biotechnology
$4.46 /

-0.04 (-0.89%)

06/28/21 Citi
Unity Biotechnology double upgraded to Buy at Citi after 50% pullback
06/28/21 Citi
Unity Biotechnology upgraded to Buy from Sell at Citi
06/07/21 H.C. Wainwright
Unity Biotechnology initiated with a Buy at H.C. Wainwright
03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
UBX Unity Biotechnology
$4.46 /

-0.04 (-0.89%)

Over a month ago
Upgrade
Unity Biotechnology double upgraded to Buy at Citi after 50% pullback » 07:13
06/28/21
06/28
07:13
06/28/21
07:13
UBX

Unity Biotechnology

$4.38 /

+0.2 (+4.78%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz upgraded Unity Biotechnology to Buy from Sell with an unchanged price target of $6, telling investors that his previous sell call has played out with the stock down about 50% since mid-February. He expects several datasets over the next 12 months to lend early validation to Unity's senolytic approach for treating age-related eye diseases and said he is making no changes to his revenue forecasts or probability of success assumptions despite the recent stock underperformance.

ShowHide Related Items >><<
UBX Unity Biotechnology
$4.38 /

+0.2 (+4.78%)

UBX Unity Biotechnology
$4.38 /

+0.2 (+4.78%)

06/28/21 Citi
Unity Biotechnology upgraded to Buy from Sell at Citi
06/07/21 H.C. Wainwright
Unity Biotechnology initiated with a Buy at H.C. Wainwright
03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
02/16/21 Citi
Unity Biotechnology downgraded to Sell from Neutral at Citi
UBX Unity Biotechnology
$4.38 /

+0.2 (+4.78%)

Upgrade
Unity Biotechnology upgraded to Buy from Sell at Citi » 07:09
06/28/21
06/28
07:09
06/28/21
07:09
UBX

Unity Biotechnology

$4.38 /

+0.2 (+4.78%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz upgraded Unity Biotechnology to Buy from Sell.

ShowHide Related Items >><<
UBX Unity Biotechnology
$4.38 /

+0.2 (+4.78%)

UBX Unity Biotechnology
$4.38 /

+0.2 (+4.78%)

06/07/21 H.C. Wainwright
Unity Biotechnology initiated with a Buy at H.C. Wainwright
03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
02/16/21 Citi
Unity Biotechnology downgraded to Sell from Neutral at Citi
08/18/20
Fly Intel: Top five analyst downgrades
UBX Unity Biotechnology
$4.38 /

+0.2 (+4.78%)

Initiation
Unity Biotechnology initiated with a Buy at H.C. Wainwright » 06:19
06/07/21
06/07
06:19
06/07/21
06:19
UBX

Unity Biotechnology

$4.57 /

-0.07 (-1.51%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein initiated coverage of Unity Biotechnology with a Buy rating and $12 price target. The analyst says Phase 1 clarity for biological activity of lead candidate UBX1325 in diabetic macular edema and age-related macular degeneration patients are expected in the coming months and offer a "near-term value inflection."

ShowHide Related Items >><<
UBX Unity Biotechnology
$4.57 /

-0.07 (-1.51%)

UBX Unity Biotechnology
$4.57 /

-0.07 (-1.51%)

03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
02/16/21 Citi
Unity Biotechnology downgraded to Sell from Neutral at Citi
08/18/20
Fly Intel: Top five analyst downgrades
08/18/20 Morgan Stanley
Unity Biotechnology downgraded at Morgan Stanley as UBX101 doesn't meet endpoint
UBX Unity Biotechnology
$4.57 /

-0.07 (-1.51%)

Hot Stocks
Unity Biotechnology reports granting of employment inducement awards » 08:18
06/02/21
06/02
08:18
06/02/21
08:18
UBX

Unity Biotechnology

$4.70 /

+0.22 (+4.91%)

UNITY Biotechnology…

UNITY Biotechnology announced that from May 18, 2021 through June 1, 2021, the Compensation Committee of the Board of Directors granted a new employee a stock-based award covering an aggregate of 9,000 shares of UNITY common stock, including options to purchase an aggregate of 9,000 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

ShowHide Related Items >><<
UBX Unity Biotechnology
$4.70 /

+0.22 (+4.91%)

UBX Unity Biotechnology
$4.70 /

+0.22 (+4.91%)

03/26/21 Mizuho
Unity Biotechnology price target raised to $5 from $4 at Mizuho
02/16/21 Citi
Unity Biotechnology downgraded to Sell from Neutral at Citi
08/18/20
Fly Intel: Top five analyst downgrades
08/18/20 Morgan Stanley
Unity Biotechnology downgraded at Morgan Stanley as UBX101 doesn't meet endpoint
UBX Unity Biotechnology
$4.70 /

+0.22 (+4.91%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.